Last reviewed · How we verify
Tamoxifen Citrate Tablets
Tamoxifen Citrate Tablets work by competitively inhibiting estrogen receptors on tumor cells.
Tamoxifen Citrate Tablets work by competitively inhibiting estrogen receptors on tumor cells. Used for Adjuvant treatment of breast cancer, Treatment of metastatic breast cancer.
At a glance
| Generic name | Tamoxifen Citrate Tablets |
|---|---|
| Sponsor | Shandong Suncadia Medicine Co., Ltd. |
| Drug class | Selective estrogen receptor modulator (SERM) |
| Target | Estrogen receptor |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
This action results in the inhibition of estrogen-dependent growth of tumors, particularly in breast cancer. Tamoxifen Citrate Tablets have a partial agonist effect on the uterus, which may lead to endometrial cancer in some cases.
Approved indications
- Adjuvant treatment of breast cancer
- Treatment of metastatic breast cancer
Common side effects
- Hot flashes
- Endometrial cancer
- Vaginal discharge
- Nausea
- Vomiting
Key clinical trials
- A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence (PHASE3)
- A Phase III Trial Comparing HRS-8080 With Standard Endocrine Therapy in Patients With High-Risk Early Breast Cancer (PHASE3)
- Long-term Follow-up of the TAM-01 Study and Pooled Analysis of Low-dose Tamoxifen Studies in Non-invasive or Microinvasive Breast Neoplasms
- A Study of MK-5684 in People With Certain Solid Tumors (MK-5684-015/OMAHA-015) (PHASE2)
- A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer (PHASE3)
- Phase 2 Study of Amcenestrant (SAR439859) Versus Physician's Choice in Locally Advanced or Metastatic ER-positive Breast Cancer (PHASE2)
- Assessing the Efficacy and Safety of Anti-HER2 Therapy in Nigerian Women With HER2+ Breast Cancer Before and After Surgery (PHASE2)
- Umbrella Trial of Subtype-Targeted Therapies in ER+/HER2- Breast Cancer (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Tamoxifen Citrate Tablets CI brief — competitive landscape report
- Tamoxifen Citrate Tablets updates RSS · CI watch RSS
- Shandong Suncadia Medicine Co., Ltd. portfolio CI